159 related articles for article (PubMed ID: 36028237)
1. Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab.
Potts J; Lee RR; Hilliard CA
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 36028237
[TBL] [Abstract][Full Text] [Related]
2. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.
Reschke R; Mockenhaupt M; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2019 Sep; 17(9):942-948. PubMed ID: 31210413
[No Abstract] [Full Text] [Related]
3. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
5. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
Dasanu CA
J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
[TBL] [Abstract][Full Text] [Related]
7. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
8. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
9. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
[TBL] [Abstract][Full Text] [Related]
10. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
Shah KM; Rancour EA; Al-Omari A; Rahnama-Moghadam S
Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142712
[TBL] [Abstract][Full Text] [Related]
11. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
[TBL] [Abstract][Full Text] [Related]
13. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
14. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
15. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
[No Abstract] [Full Text] [Related]
16. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-induced lichenoid penile ulceration and re-emergent mucocutaneous eruption treated with hydroxychloroquine.
Headd VA; Mathien A; Pei S; Kuraitis D
Australas J Dermatol; 2024 Jun; 65(4):e97-e99. PubMed ID: 38337182
[No Abstract] [Full Text] [Related]
18. Nivolumab-induced Stevens-Johnson syndrome: Not only due to PD-1 inhibition.
Rodríguez-Otero N; Chamorro-Pérez J; Fernández-Lozano C; Elías-Sáenz I; Berná-Rico E; de Nicolás-Ruanes B; Meléndez-Gispert MR; Moreno-García Del Real C; Martínez-Botas J; Cortés-Salgado A; Solano-Solares E
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2936-2938.e1. PubMed ID: 37308058
[No Abstract] [Full Text] [Related]
19. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
Diaz-Perez JA; Beveridge MG; Victor TA; Cibull TL
J Cutan Pathol; 2018 Jun; 45(6):434-438. PubMed ID: 29468713
[TBL] [Abstract][Full Text] [Related]
20. Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions.
Cheraghlou S; Levy LL
Clin Dermatol; 2020; 38(6):679-692. PubMed ID: 33341201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
